2024
Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
Sehgal K, Shi R, Pappa T, Min J, Oakley L, ONeill A, Dennis M, Deshpande H, Haddad R, Lorch J. Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). Journal Of Clinical Oncology 2024, 42: 6109-6109. DOI: 10.1200/jco.2024.42.16_suppl.6109.Peer-Reviewed Original ResearchMetastatic medullary thyroid carcinomaTreatment-related adverse eventsProgression-free survivalRAIR-DTCProgression-freeOverall survivalClinical trialsMedian progression-free survivalCycle 2 onwardsMedian overall survivalPhase II clinical trialMedullary thyroid carcinomaPhase II trialMulti-kinase inhibitorII clinical trialsSimon's two-stage designRECIST v1.1Systemic therapyTolerated doseStage 2Thyroid carcinomaMedian agePlanned escalationTherapeutic optionsInhibitor exposure
2012
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
Deshpande H, Sheth K, Sosa J, Roman S. Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer. Clinical Medicine Insights Oncology 2012, 6: cmo.s8305. PMID: 23133319, PMCID: PMC3489097, DOI: 10.4137/cmo.s8305.Peer-Reviewed Original ResearchMedullary thyroid carcinomaProgressive medullary thyroid carcinomaAdvanced medullary thyroid carcinomaManagement of MTCMedullary thyroid cancerAdvanced diseasePharmacotherapy optionsConventional chemotherapyThyroid cancerThyroid carcinomaNovel treatmentsUS FoodDrug AdministrationTreatmentTherapyDiseaseEfficacyTolerabilityChemotherapyPatientsCarcinomaVandetanibCancerAdministration